Ann: Amended June Quarterly Reports (amended App. 4C), page-4

"Cost reduction strategy implemented in June quarter including reduction in material R&D costs, with future non-core trials also deferred."

So to reduce costs they're going to scale back R&D and trials.... not reduce staff and admin costs or Roby's payments.

If I was a holder I would be wanting to seek clarification about what they see as "future non-core trials"

Last time they made statements like that, nearly all trials and research activity was dropped....

So much for them buying the research company saving them funds in research.... looks like that was just a big payout for their Chief Medical Officer... how much did they pay for that again? $6m?

Finally, take a look at the gross profit margin. All but non existent gross profit margin. Won't matter how much they sell at those margins, they'll never get to cash flow break even.

Wasn't Roby and Brett promising cash flow positive by this time last year? @divvv10 pretty sure you were spruiking that narrative? Lol